Linotryp 50 SR Tablet contains Amitriptyline 50 mg, a tricyclic antidepressant primarily indicated for the treatment of major depressive disorder, neuropathic pain, and certain anxiety disorders. Amitriptyline exerts its therapeutic effects by inhibiting the reuptake of norepinephrine and serotonin, thereby enhancing neurotransmitter activity in the central nervous system. The sustained-release formulation ensures a gradual release of the active ingredient, promoting steady plasma concentrations and improving patient compliance by reducing dosing frequency. Linotryp 50 SR is also utilized off-label for migraine prophylaxis and chronic pain syndromes. It should be administered under medical supervision, with dosage individualized based on clinical response and tolerability. Common adverse effects include dry mouth, sedation, dizziness, and gastrointestinal disturbances, while more serious side effects such as cardiac arrhythmias and orthostatic hypotension warrant close monitoring, especially in patients with pre-existing cardiovascular conditions. Caution is advised when prescribing to elderly patients or those with a history of seizures. Contraindications include recent myocardial infarction and concurrent use of monoamine oxidase inhibitors. Regular follow-up is essential to assess therapeutic efficacy and detect potential adverse reactions. Linotryp 50 SR should be stored in a cool, dry place away from direct sunlight and out of reach of children.